Statistics from Altmetric.com
We have read with interest the article by Nakaoka and colleagues1 on the efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis. The authors have presented a randomised controlled trial in which they suggest a preference for tocilizumab over placebo for time to relapse of Takayasu arteritis, without any new safety concerns. We would like to draw attention to a few points in this regard.
First, Takayasu arteritis and giant cell arteritis share some similarities in terms of …